In an effort to provide a broad range of support for people living with bleeding disorders, the Patient Access Netowrk Foundation and the National Hemophilia Foundation have announced a new alliance.
In an effort to provide a broad range of support for people living with bleeding disorders, the Patient Access Netowrk Foundation and the National Hemophilia Foundation have announced a new alliance. Offering both financial and support services, the 2 foundations will provide up to $5800 per year in financial assistance to go toward deductibles, co-pays, and coinsurance costs. Eligible patients will also be able to receive $4500 per year in financial assitance for out-of-pocket costs.
Patients must be receiving treatment for hemophilia; must be residing and receiving treatment in the United States; must have health insurance; and the medication must be covered by their insurance and be listed on the PAN Foundation's list of covered medications. Read more about the alliance.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More